Evidence map›Paper›PMID 39046546›Full record

ArticleInternational journal of colorectal disease2024

Role of blood metabolites in mediating the effect of gut microbiome on the mutated-RAS/BRAF metastatic colorectal cancer-specific survival.

Yaoxian Xiang, Chan Zhang, Jing Wang, Yurong Cheng, Kangjie Wang, Li Wang, Yingying Tong, Dong Yan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of colorectal disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yaoxian XiangDepartment of Oncology, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, 101149, China.
Chan ZhangDepartment of Oncology, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, 101149, China.
Jing WangDepartment of Oncology, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, 101149, China.
Yurong ChengDepartment of Oncology, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, 101149, China.
Kangjie WangDepartment of Oncology, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, 101149, China.
Li WangDepartment of Oncology, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, 101149, China.
Yingying TongDepartment of Oncology, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, 101149, China.
Dong YanDepartment of Oncology, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, 101149, China. yd15yt88@163.com.

Funding

Capital Health Research and Development of Special Fund 2022-2-7083
6 · The paper itself

Abstract

backgroundRecent studies have linked alterations in the gut microbiome and metabolic disruptions to the invasive behavior and metastasis of colorectal cancer (CRC), thus affecting patient prognosis. However, the specific relationship among gut microbiome, metabolite profiles, and mutated-RAS/BRAF metastatic colorectal cancer (M-mCRC) remains unclear. Furthermore, the potential mechanisms and prognostic implications of metabolic changes induced by gut microbiome alterations in patients with M-mCRC still need to be better understood.

methodsWe conducted Mendelian randomization (MR) to evaluate the causal relationship of genetically predicted 196 gut microbiome features and 1400 plasma metabolites/metabolite ratios on M-mCRC-specific survival. Additionally, we identified significant gut microbiome-metabolites/metabolite ratio associations based on M-mCRC. Metabolite information was annotated, and functional annotation and pathway enrichment analyses were performed on shared proteins corresponding to significant metabolite ratios, aiming to reveal potential mechanisms by which gut microbiome influences M-mCRC prognosis via modulation of human metabolism.

resultsWe identified 11 gut microbiome features and 49 known metabolites/metabolite ratios correlated with M-mCRC-specific survival. Furthermore, we identified 17 gut microbiome-metabolite/metabolite ratio associations specific to M-mCRC, involving eight lipid metabolites and three bilirubin degradation products. The shared proteins corresponding to significant metabolite ratios were predominantly localized within the integral component of the membrane and exhibited enzymatic activities such as glucuronosyltransferase and UDP-glucuronosyltransferase, crucial in processes such as glucuronidation, bile secretion, and lipid metabolism. Moreover, these proteins were significantly enriched in pathways related to ascorbate and aldarate metabolism, pentose and glucuronate interconversions, steroid hormone biosynthesis, and bile secretion.

conclusionOur study offers novel insights into the potential mechanisms underlying the impact of the gut microbiome on the prognosis of M-mCRC. These findings serve as a meaningful reference for exploring potential therapeutic targets and strategies in the future.

Indexed as

Colorectal NeoplasmsGastrointestinal MicrobiomeMutationNeoplasm MetastasisProto-Oncogene Proteins B-rafHumansMendelian Randomization AnalysisMetabolomePrognosisras ProteinsSurvival AnalysisBRAF protein, humanProto-Oncogene Proteins B-rafras ProteinsCausal relationshipGut microbiomeMendelian randomization(MR)MetabolitesMutated-RAS/BRAF metastatic colorectal cancer(M-mCRC)Survival

Identifiers

PMID39046546
PMCPMC11269474

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.